Primary use in medicine is in the treatment of major depressive disorder.

It is being targeted as the first non-hormonal based treatment for menopause.

It is an extended release tablet for oral administration that contains desvenlafaxine succinate, a structurally novel SNRI for the treatment of MOD, Desvenlafaxine is the major active metabolite of the antidepressant venlafaxine, a medication used to treat major depressive disorder.

Indications:

MOA: selective serotonin and norepinephrine reuptake inhibitor

major depressive disorder

Pharmacokinetics

• metabolized by conjugation, 3A4 minor metabolic pathway
• 45% excreted unchanged in urine

Available Packaging: 10*10